Commercialization
- Knocking on a Difficult Door
-
Selling to managed care organizations requires an entirely different approach than traditional pharmaceutical detailing.
- Same Difference
-
Across Europe, incentive programs have been designed, redesigned and implemented to encourage physicians to prescribe generic medications. Although the practice may help reduce costs, does it represent value for everyone?
- Access to Innovation
-
Ideally, pharmaceutical pricing provides an incentive for innovation and also makes quality medicines accessible to all. Achieving this delicate balance, however, is proving to be a difficult proposition.
- Choosing Words Wisely
-
Semiotics and the process of studying vocabulary has found a niche in the pharmaceutical industry.
- A Bridge Too Far
-
A tangled web of patients, profits, patents and politics makes compulsory licensing a perennial source of frustration for pharmaceutical manufacturers trying to protect their innovative discoveries.
- Special Delivery
-
Pharmaceutical companies are learning the importance of having well-trained, highly qualified specialty sales reps.
- Changing Tides
-
pharmaceutical companies and academic institutions are looking for ways to offer continuing medical education programs free from conflicts of interest.
- Leveling the Field
-
As the U.K. experience has shown, proving the safety, efficacy and value of medications can be a murky affair.
- Fair Exchange
-
Parallel trade of pharmaceuticals in Europe offers minimal benefit to consumers and payers, but the practice may push product development to the United States and other countries where research dollars and less stringent regulations abound.
- Obey the Signals
-
As the call for heightened pharmacovigilance grows more urgent, industry stakeholders are developing new tools to identify potential safety hazards and communicate risk.
Web Exclusives
- Turning the Corner
-
After decades of neglect, leading to a rapid increase in incidence, tuberculosis started gaining attention from industrialized nations over the past 10 years. With this new focus, TB’s incidence has started to decrease—but barely.
- A Weighty Problem
-
As pharmaceutical companies search for a blockbuster fat-fighting drug, the biggest battle is against side effects.